Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Darunavir

FDA-approved product (tablet, oral), marketed as Darunavir, Prezista.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Darunavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Immunodeficiency disease
  • Infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
FDA pharmacologic class
Protease Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE10

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Darunavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Darunavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice

    NCT03042390 · start 2016-12-23

    Registered record
    Registry ID
    NCT03042390
    Conditions
    HIV Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-12-23
    Completion
    2017-05-09
    Enrolment
    762

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors

    NCT02738502 · start 2016-07-06

    Registered record
    Registry ID
    NCT02738502
    Conditions
    Maternal-fetal Infection Transmission
    Interventions
    darunavir monotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-07-06
    Completion
    2020-07-16
    Enrolment
    91

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMaternal-fetal Infection Transmission
    Interventiondarunavir monotherapy
    PhasePhase 2
    Registry statusCompleted

  • ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment

    NCT02735863 · start 2016-05

    Registered record
    Registry ID
    NCT02735863
    Conditions
    HIV Infection
    Interventions
    ABX464; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-05
    Completion
    2018-01-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionABX464; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Interaction With HIV Antiretroviral Agents

    NCT02556268 · start 2016-02-23

    Registered record
    Registry ID
    NCT02556268
    Conditions
    HIV-DDI
    Interventions
    Riociguat (Adempas, BAY 63-2521); ATRIPLA; COMPLERA; STRIBILD; TRIUMEQ; Antiretroviral protease inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02-23
    Completion
    2016-12-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-DDI
    InterventionRiociguat (Adempas, BAY 63-2521); ATRIPLA; COMPLERA; STRIBILD +2 more
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

    NCT02616029 · start 2015-12-17

    Registered record
    Registry ID
    NCT02616029
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-12-17
    Completion
    2019-07-11
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF
    PhasePhase 3
    Registry statusCompleted

  • Research In Viral Eradication of HIV Reservoirs

    NCT02336074 · start 2015-11-27

    Registered record
    Registry ID
    NCT02336074
    Conditions
    HIV
    Interventions
    Combination Antiretroviral Therapy (cART); Raltegravir; Vorinostat; ChAdV63.HIVconsv (ChAd); MVA.HIVconsv (MVA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-11-27
    Completion
    2023-03-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionCombination Antiretroviral Therapy (cART); Raltegravir; Vorinostat; ChAdV63.HIVconsv (ChAd) +1 more
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

    NCT02605954 · start 2015-11-18

    Registered record
    Registry ID
    NCT02605954
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-18
    Completion
    2018-01-24
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    PhasePhase 3
    Registry statusCompleted

  • HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

    NCT02513147 · start 2015-06

    Registered record
    Registry ID
    NCT02513147
    Conditions
    HIV-1
    Interventions
    Dolutegravir; PI; 2 NRTI; 2 NRTI
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-06
    Completion
    2016-11
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionDolutegravir; PI; 2 NRTI; 2 NRTI
    PhasePhase 4
    Registry statusCompleted

  • Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

    NCT02247687 · start 2014-12

    Registered record
    Registry ID
    NCT02247687
    Conditions
    HIV-1 Infection; Treatment Resistant Disorders; Viremia
    Interventions
    Protease inhibitor; Isentress® (raltegravir); Counseling arm
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2014-12
    Completion
    2015-09
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection; Treatment Resistant Disorders; Viremia
    InterventionProtease inhibitor; Isentress® (raltegravir); Counseling arm
    PhasePhase 3
    Registry statusTerminated

  • Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

    NCT02302547 · start 2014-12

    Registered record
    Registry ID
    NCT02302547
    Conditions
    HIV
    Interventions
    triple therapy; dual therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12
    Completion
    2018-09-21
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiontriple therapy; dual therapy
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject

    NCT02159599 · start 2014-07

    Registered record
    Registry ID
    NCT02159599
    Conditions
    HIV Infection
    Interventions
    Darunavir/Ritonavir; Lamivudine; Emtricitabine/tenofovir or abacavir/lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2016-04
    Enrolment
    249

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionDarunavir/Ritonavir; Lamivudine; Emtricitabine/tenofovir or abacavir/lamivudine
    PhasePhase 4
    Registry statusCompleted

  • Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART

    NCT01869634 · start 2013-06

    Registered record
    Registry ID
    NCT01869634
    Conditions
    Human Immunodeficiency Virus Infection
    Interventions
    darunavir with ritonavir and fixed-dose viread+emtricitabine daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-06
    Completion
    2016-12
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus Infection
    Interventiondarunavir with ritonavir and fixed-dose viread+emtricitabine daily
    PhasePhase 4
    Registry statusCompleted

  • Antiretroviral Therapy and Extreme Weight

    NCT01805427 · start 2012-09

    Registered record
    Registry ID
    NCT01805427
    Conditions
    HIV Infection
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-09
    Completion
    2013-11
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects

    NCT01423812 · start 2012-01

    Registered record
    Registry ID
    NCT01423812
    Conditions
    HIV
    Interventions
    Twice-daily combination Darunavir and ritonavir; Once-daily combination Darunavir and ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-01
    Completion
    2015-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionTwice-daily combination Darunavir and ritonavir; Once-daily combination Darunavir and ritonavir
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

    NCT01440569 · start 2011-09

    Registered record
    Registry ID
    NCT01440569
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    COBI; DRV; NRTIs
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09
    Completion
    2015-10
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionCOBI; DRV; NRTIs
    PhasePhase 3
    Registry statusCompleted